Physician profile
Katherine E Anglim
NPI 1770691867
$1,145.81
in general payments reported to CMS, 2019-2025
15 companies · $131 in 2025
The $131 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $102 · 2021: $57.47 · 2022: $148 · 2023: $198 · 2024: $334 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $327.15 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $305.29 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $132.96 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $60.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $49.84 | 2024 | |
| Pfizer INC. | $49.42 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.15 | 2019 | |
| Collegium Pharmaceutical, INC. | $31.76 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $28.61 | 2020-2024 | Cotempla Xr-Odt |
| Kaleo, INC. | $24.87 | 2022 | |
| Sanofi Pasteur INC. | $23.09 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $21.01 | 2024 | Flumist Quadrivalent |
| Sobi, INC | $17.78 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.34 | 2019 | |
| Genentech USA, INC. | $15.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Anglim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.